José Antonio Iribarren
A5041223946- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Orthopedic Infections and Treatments
- Chronic Lymphocytic Leukemia Research
- Menopause: Health Impacts and Treatments
- Eosinophilic Esophagitis
- Viral-associated cancers and disorders
- Pharmacological Effects and Toxicity Studies
- Infectious Diseases and Tuberculosis
- Diabetes Treatment and Management
- Heart rate and cardiovascular health
- Cardiovascular Function and Risk Factors
- Immunodeficiency and Autoimmune Disorders
- Orthopaedic implants and arthroplasty
- Surgical site infection prevention
- HIV, Drug Use, Sexual Risk
- Tryptophan and brain disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmaceutical Practices and Patient Outcomes
- Estrogen and related hormone effects
- Phytoestrogen effects and research
- Lymphoma Diagnosis and Treatment
Biogipuzkoa Health Research Institute
2012-2022
Hospital Universitari Germans Trias i Pujol
2012
IrsiCaixa
2012
With the purpose of reducing well-known negative impact late presentation (LP) on people living with HIV (PLWH), guidelines early diagnosis were published in 2014 Spain, but since then no data LP prevalence have been published. To estimate and risk factors to evaluate their development clinical outcomes Cohort Spanish HIV/AIDS Research Network (CoRIS) during 2004-2018.CoRIS is an open prospective multicenter cohort PLWH, adults, naive ART at entry. was defined as CD4 count ≤350 cells/μL or...
We report the identification of a new HIV-1 circulating recombinant form (CRF47_BF) derived from subtypes B and F. It was initially identified in protease-reverse transcriptase sequences nine individuals three separate regions Spain who acquired infection via sexual contact. All formed strongly supported phylogenetic cluster, branching apart all known CRFs, bootscan analyses were BF mosaics with two coincident breakpoints. Two epidemiologically unlinked viruses sequenced near full-length...
Objectives: The aim of this study was to examine the impact late presentation (CD4 + cell count <350 cells/μl or an AIDS-defining event) on effectiveness and safety initial antiretroviral therapy (ART) evaluate whether treatment response depends first-line ART regimen in presenters. Design: ART-naive adults from Cohort Spanish HIV/AIDS Research Network (CoRIS) starting triple between 2010 2018. Methods: We used multivariable models assess differences viral suppression (viral load <50...
To estimate the prevalence and severity of menopausal symptoms anxiety/depression to assess differences according status among women living with HIV aged 45-60 years from cohort Spanish HIV/AIDS Research Network (CoRIS).Women were interviewed by phone between September 2017 December 2018 determine whether they had experienced anxiety/depression. The Menopause Rating Scale was used evaluate related menopause in three subscales: somatic, psychologic urogenital; 4-item Patient Health...
The extraordinary genetic variability of human immunodeficiency virus type 1 (HIV-1) group M has led to the identification 10 subtypes, 102 circulating recombinant forms (CRFs) and numerous unique forms. Among CRFs, 11 derived from subtypes B C have been identified in China, Brazil, Italy. Here we identify a new HIV-1 CRF_BC Northern Spain. Originally, phylogenetic cluster 15 viruses subtype protease-reverse transcriptase was an molecular surveillance study Spain, most them individuals...
To assess the attitudes and opinions about generic antiretroviral drugs (ARVs) single-tablet regimen (STR) de-simplification among physicians prescribing HIV treatment in cohort of Spanish HIV/AIDS Research Network (CoRIS).An online questionnaire with 27 structured questions was sent to all (n=199) who prescribed ARVs 45 centres participating cohort.A total 169 (84.9%) answered questionnaire. Only 4.1% would never prescribe ARVs, but 53.3% not them if number pills per day increased 89.3%...
To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with most frequently prescribed first-line treatment regimens, among antiretroviral-naive people HIV from CoRIS, a multicentre cohort in Spain, 2018-23.
Purpose Due to the relative low age of HIV‐infected patients, Framingham risk score (FRS) usually estimates a CVD risk. Lifetime estimations use developing over course an individual's remaining lifetime and may be useful in communicating young patients. Our aim is estimate representative sample HIV patients under antiretroviral therapy Spain. Methods Cross‐sectional analysis 10 units across Spain, including information on demographics, disease status, treatment history cardiovascular factors...